NASDAQ: ADMA · Biotechnology
ADMA Biologics (ADMA) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values ADMA Biologics (ADMA) at $15.96 a share. The stock last closed at $13.47, which puts the model's fair value 18.5% above the price. On the model's bands that reads as Undervalued.
Revalued . Price is the close of 16 Nov 2026. ADMA Biologics, Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $14.86 to $15.96 (+7.4%). The multiple the model anchors on moved, lifting the fair value: most of the move.
What the model makes of itThe price of $13.47 is 18.5% below it: Undervalued, on a medium evidence grade.
What's nextNext report on 24 Feb 2027. Options prices imply a move of about 15% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give ADMA?
The calibrated range for ADMA over 63 trading days is $11.37 to $16.10. It sits around the last close, and its width comes from the volatility that ADMA's own options imply (51% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $9.88 to $24.58. In 61% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
ADMA Biologics, Inc. is a biopharmaceutical company. It develops, manufactures and commercialises advanced biologic therapies derived from blood plasma.
Faircurve's model gives a fair value of $15.96 a share for ADMA Biologics, the midpoint of 2,000 simulations, on the run of 14 Nov 2026. The previous run, on 7 Nov 2026, gave $14.86, so the fair value moved +7.4%. The reason, in the model's own words: the multiple it anchors on moved, lifting the fair value, most of the move. The calibrated range over 63 trading days is $11.63 to $16.23, built from the volatility the stock's own options imply. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is Medium, based on input completeness, the number and agreement of comparable companies, and the width of outcomes. It does not say whether the fair value is right.
ADMA's overall quality score is 68 out of 100 against comparable companies. Profitability scores 100: ROIC 35.1%, peer median -54.4%. Capital discipline scores 100: net buybacks 6.2% of market value, peer median 0.0%. Stability scores 0: EBITDA margin downside volatility 29.7 pts over five years. Comparables are Vericel Corporation (VCEL), Acadia Pharmaceuticals Inc. (ACAD) and Fortrea Holdings Inc. (FTRE).
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does ADMA report earnings, and how has the stock reacted?
ADMA Biologics's next earnings report is scheduled for 24 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 12.0% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. ADMA's 30 day implied volatility works out to about 14.9% over one month.
Around its last 3 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across ADMA's last 8 reports, ignoring direction, was 12.3%.
Earlier reports are left out: the options record before 28 Mar 2026 is not comparable.
What the options market has priced for a month's move in ADMA
How does ADMA score on business quality?
ADMA Biologics's overall quality score is 68 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 100 | 35.1%ROIC | -54.4% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 40 | 0.73xFCF / net income | |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 61 | 19.6%Revenue growth, trailing | |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 100 | 6.2%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 76 | 0.31xNet debt / EBITDA | |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 0 | 29.7 ptsEBITDA margin downside volatility, 5y |
How does ADMA compare with similar companies?
The companies in biotechnology closest to ADMA Biologics in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| VCEL Vericel Corporation | $57.48 | $65.96 | +14.8% | Fairly valued |
| ACAD Acadia Pharmaceuticals Inc. | $18.67 | $23.24 | +24.5% | Undervalued |
| XNCR Xencor, Inc. | $35.40 | $35.72 | +0.9% | Low evidence grade |
| RCUS Arcus Biosciences, Inc. | $16.86 | $16.32 | -3.2% | Low evidence grade |
| HRMY Harmony Biosciences Holdings, Inc. | $32.96 | $33.93 | +2.9% | Low evidence grade |
| FTRE Fortrea Holdings Inc. | $19.79 | $24.79 | +25.3% | Undervalued |
| PTCT PTC Therapeutics, Inc. | $60.97 | $74.62 | +22.4% | Low evidence grade |
| SRPT Sarepta Therapeutics, Inc. | $15.13 | $19.51 | +28.9% | Low evidence grade |
What the comparable companies' multiples alone would give for ADMA, the peer-implied price, is $169.78 a share on this run. The fair value weighs that against the company's own multiple.
ADMA Biologics at a glance
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma.
- Market value
- $3.0B
- Sector
- Healthcare
- Industry
- Biotechnology
- Revenue expected, next twelve months
- $603M
- Consensus revenue growth, next fiscal year
- +4.8%
- Analysts with estimates
- 3
- Beta to the US market
- -0.26
- First valued by Faircurve
- 11 Jul 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. ADMA was among them.
How the fair value is worked out: the model prices ADMA Biologics on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for ADMA was $14.86. As of 14 Nov 2026 it is $15.96, a change of +7.4%. The multiple the model anchors on moved, lifting the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about ADMA Biologics's valuation
Is ADMA Biologics stock undervalued or overvalued?
On Faircurve's model, ADMA reads as Undervalued as of 14 Nov 2026. The model's fair value is $15.96 a share against a last close of $13.47, a gap of +18.5%.
What is ADMA's fair value?
$15.96 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $9.88 to $24.58.
What price range does the model give ADMA?
$11.37 to $16.10 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does ADMA Biologics report earnings next?
The next report is scheduled for 24 Feb 2027. Companies can move their dates.
How much has ADMA moved on past earnings reports?
Across its last 8 reports the median two session move was 12.3%, ignoring direction. The largest was +18.9% around the report of 4 Nov 2026.
How confident is the model in this valuation?
The model's evidence grade for ADMA is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on ADMA
The model holds no idea open on ADMA today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on ADMA with their outcomes. A free account is enough.